CAMBRIDGE, Mass.--(BUSINESS WIRE)--Elixir Pharmaceuticals, Inc., announced today the initiation of its final, pivotal phase III clinical study of mitiglinide for the treatment of patients with type 2 diabetes. The phase III clinical study is expected to be completed in mid-2008, with data available shortly thereafter. The results from this study will supplement the existing clinical database (phases I-III) of nearly 4,000 patients to form the basis of the Company’s anticipated New Drug Application submission to the FDA.
